Compare CIF & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIF | GDTC |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 24.8M |
| IPO Year | N/A | 2023 |
| Metric | CIF | GDTC |
|---|---|---|
| Price | $1.75 | $1.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 43.9K | ★ 79.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $1.47 | $1.50 |
| 52 Week High | $1.77 | $4.05 |
| Indicator | CIF | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 53.15 | 38.67 |
| Support Level | $1.68 | $1.71 |
| Resistance Level | $1.75 | $1.68 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 66.48 | 19.55 |
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.